Palonosetron hydrochloride and Lenvatinib drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Palonosetron hydrochloride (palonosetron hydrochloride) and Lenvatinib (lenvatinib). Common drug interactions include febrile neutropenia among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Palonosetron hydrochloride and Lenvatinib. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Palonosetron hydrochloride?

Palonosetron hydrochloride has active ingredients of palonosetron hydrochloride. eHealthMe is studying from 2,088 Palonosetron hydrochloride users. Check the latest studies of Palonosetron hydrochloride.

What is Lenvatinib?

Lenvatinib has active ingredients of lenvatinib. eHealthMe is studying from 3,587 Lenvatinib users. Check the latest studies of Lenvatinib.

On Jul, 19, 2026

18 people who take Palonosetron hydrochloride and Lenvatinib together, and have interactions are studied.

Palonosetron hydrochloride and Lenvatinib drug interactions.

What are the common drug interactions of Palonosetron Hydrochloride and Lenvatinib, by gender? *:

female:

Febrile neutropenia (fever with reduced white blood cells)
Malaise (a feeling of general discomfort or uneasiness)
Stomatitis (inflammation of mucous membrane of mouth)
Pleural effusion (water on the lungs)

male:

Diarrhoea
Cholangitis sclerosing (infection and obstruction of bile duct)
Decreased appetite
Gastrointestinal perforation (hole in the digestive tract)
Vomiting
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Blood creatinine increased
Cardiac failure
Febrile neutropenia (fever with reduced white blood cells)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)

What are the common drug interactions of Palonosetron Hydrochloride and Lenvatinib, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Anaemia (lack of blood)
Blood creatinine increased
Febrile neutropenia (fever with reduced white blood cells)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Platelet count decreased
Sepsis (a severe blood infection that can lead to organ failure and death)
White blood cell count decreased

60+:

Stomatitis (inflammation of mucous membrane of mouth)
Diarrhoea
Abdominal pain
Decreased appetite
Gastrointestinal perforation (hole in the digestive tract)
Vomiting
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Cardiac failure
Osteomyelitis (infection of bone)
Pleural effusion (water on the lungs)

What are the existing conditions these people have? *

Oesophageal Cancer Metastatic (cancer of oesophagues spreads to other part): 8 people, 44.44%
Oesophageal Adenocarcinoma (a cancer tumour of an epithelium in oesophagus): 5 people, 27.78%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 5 people, 27.78%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Palonosetron hydrochloride and Lenvatinib?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously